CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma

Published:2018-12-31 Issue:1 Volume:69 Page:143-159
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Liu Long-Zi¹,Zhang Zhao¹,Zheng Bo-Hao¹,Shi Yang²,Duan Men¹,Ma Li-Jie¹,Wang Zhi-Chao¹,Dong Liang-Qing¹,Dong Ping-Ping³,Shi Jie-Yi¹,Zhang Shu¹,Ding Zhen-Bin¹,Ke Ai-Wu¹,Cao Ya⁴,Zhang Xiao-Ming⁵,Xi Ruibin²,Zhou Jian¹⁶⁷,Fan Jia¹⁶⁷,Wang Xiao-Ying¹,Gao Qiang¹⁷

Affiliation:

1. Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education); Fudan University; Shanghai China

2. Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies; Peking University; Beijing China

3. Department of Gastroenterology and Hepatology, Zhongshan Hospital; Fudan University; Shanghai China

4. Cancer Research Institute, Xiangya School of Medicine; Central South University; Hunan China

5. Key Laboratory of Molecular Virology & Immunology, Institute Pasteur of Shanghai; Chinese Academy of Sciences; Shanghai China

6. Institute of Biomedical Sciences; Fudan University; Shanghai China

7. State Key Laboratory of Genetic Engineering; Fudan University; Shanghai China

Funder

National Natural Science Foundation of China

Basic Research Project from Technology Commission of Shanghai Municipality

National Program for Special Support of Eminent Professionals and Science

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.30134/fullpdf

Reference43 articles.

1. Disparities in liver cancer occurrence in the United States by race/ethnicity and state;Islami;CA Cancer J Clin,2017

2. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017

3. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial;El-Khoueiry;Lancet,2017

4. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment;Giannelli;Gut,2014

5. Roles for chemokines in liver disease;Marra;Gastroenterology,2014

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of SPP1+ macrophages in promoting cancer stemness via vitronectin and CCL15 signals crosstalk in liver cancer;Cancer Letters;2024-11

2. Signaling molecules in the microenvironment of hepatocellular carcinoma;Functional & Integrative Genomics;2024-08-29

3. New perspectives on chemokines in hepatocellular carcinoma therapy: a critical pathway for natural products regulation of the tumor microenvironment;Frontiers in Immunology;2024-08-14

4. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside;Experimental Hematology & Oncology;2024-08-01

5. Macronutrient-differential dietary pattern impacts on body weight, hepatic inflammation, and metabolism;Frontiers in Nutrition;2024-05-29